Last reviewed · How we verify
Rasagiline mesylate plus Mirapex
Rasagiline mesylate plus Mirapex is a MAO-B inhibitor plus dopamine agonist combination Small molecule drug developed by Teva Neuroscience, Inc.. It is currently FDA-approved for Parkinson's disease.
This combination pairs a monoamine oxidase B inhibitor with a dopamine agonist to enhance dopaminergic signaling in the brain for Parkinson's disease management.
This combination pairs a monoamine oxidase B inhibitor with a dopamine agonist to enhance dopaminergic signaling in the brain for Parkinson's disease management. Used for Parkinson's disease.
At a glance
| Generic name | Rasagiline mesylate plus Mirapex |
|---|---|
| Sponsor | Teva Neuroscience, Inc. |
| Drug class | MAO-B inhibitor plus dopamine agonist combination |
| Target | Monoamine oxidase B and dopamine D2/D3 receptors |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Rasagiline is a selective MAO-B inhibitor that prevents the breakdown of dopamine, while Mirapex (pramipexole) is a dopamine D2/D3 receptor agonist that directly stimulates dopamine receptors. Together, they increase dopamine availability and receptor activation, providing complementary symptomatic relief in Parkinson's disease by addressing both dopamine preservation and receptor stimulation.
Approved indications
- Parkinson's disease
Common side effects
- Dyskinesia
- Dizziness
- Nausea
- Hallucinations
- Somnolence
- Orthostatic hypotension
Key clinical trials
- Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease (PHASE2, PHASE3)
- A Phase 3 Study With P2B001 in Subjects With Early Parkinson's (PHASE3)
- Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease (PHASE4)
- A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rasagiline mesylate plus Mirapex CI brief — competitive landscape report
- Rasagiline mesylate plus Mirapex updates RSS · CI watch RSS
- Teva Neuroscience, Inc. portfolio CI
Frequently asked questions about Rasagiline mesylate plus Mirapex
What is Rasagiline mesylate plus Mirapex?
How does Rasagiline mesylate plus Mirapex work?
What is Rasagiline mesylate plus Mirapex used for?
Who makes Rasagiline mesylate plus Mirapex?
What drug class is Rasagiline mesylate plus Mirapex in?
What development phase is Rasagiline mesylate plus Mirapex in?
What are the side effects of Rasagiline mesylate plus Mirapex?
What does Rasagiline mesylate plus Mirapex target?
Related
- Drug class: All MAO-B inhibitor plus dopamine agonist combination drugs
- Target: All drugs targeting Monoamine oxidase B and dopamine D2/D3 receptors
- Manufacturer: Teva Neuroscience, Inc. — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Parkinson's disease
- Compare: Rasagiline mesylate plus Mirapex vs similar drugs
- Pricing: Rasagiline mesylate plus Mirapex cost, discount & access